Pharmacokinetics (PK) and Safety of A Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

This is an open-label, 2-part single dose study: Part 1 will include participants with mild,
moderate, and severe renal impairment, and Part 2 will include participants with end stage
renal disease (ESRD) undergoing HD. Participants in Part 1 will receive a single IV dose of
MK-3866, and plasma and urine samples will be collected over pre-specified time intervals.
Participants in Part 2 will receive a single IV dose of MK-3866 on two separate occasions: in
Period 1 immediately following their normally-scheduled HD, and in Period 2 approximately 30
minutes prior to their normally-scheduled HD. Plasma, urine, and dialysate samples will be
collected over pre-specified time intervals for Part 2.

Inclusion Criteria:

- Females of non-childbearing potential. Male participants with female partner(s) of
child-bearing potential agree to use a medically acceptable method of contraception
during the study and for 90 days after dosing. If partner is pregnant, males agree to
use a condom; if partner is of child-bearing potential, partner must use additional
birth control

- Male participants agree not to donate sperm from the first dose until 90 days after
dosing

- Adequate venous access

Renal Impaired Participants

- Liver function tests (serum alanine aminotransferase [ALT] and aspartate
aminotransferase [AST]) and serum bilirubin (total and direct) within upper limit of
normal

- Panels A, B, and C: no clinically significant change in renal status at least 1 month
prior to dosing and not currently or previously been on hemodialysis

- Panel E only: ESRD maintained on stable regimen of at least 3 times per week HD for at
least 3 months prior to first dosing

Healthy Participants

- Age within ± 15 years of the mean age of participants with impaired renal function to
which the healthy participant is matched

- Medically healthy as per medical history, physical examination, vital signs, 12-lead
electrocardiograms (ECGs), and clinical laboratory safety tests

- Blood urea nitrogen, liver function tests (ALT, AST, alkaline phosphatase [ALP]), and
serum bilirubin (total and direct) within upper limit of normal.

Exclusion Criteria:

- Mentally/legally incapacitated, or significant emotional problems or significant
psychiatric disorder

- History of clinically significant endocrine, gastrointestinal, cardiovascular,
hematological, hepatic, immunological, respiratory, genitourinary or major
neurological abnormalities or diseases

- History of any illness that might confound the results of the study or poses an
additional risk to the participant by their participation in the study

- Clinically significant history of cancer

- Smoker and/or has used nicotine or nicotine-containing products within 3 months prior
to screening

- Female participants of childbearing potential, pregnant, or lactating

- Positive results for urine or saliva drug screen and/or urine or breath alcohol screen
at screening or check-in

- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBsAg), or hepatitis C virus (HCV)

- Consumes more than 3 glasses of alcoholic beverages within 6 months of screening

- Consumes excessive amounts of coffee, tea, cola, energy-drinks, or other caffeinated
beverages per day

- Major surgery, donated or lost 1 unit of blood within 4 weeks prior to screening, or
donated plasma within 7 days prior to dosing in Part 1 or first dose in Part 2

Renal Impaired Participants

- Panels A, B, and C: Failed renal transplant or has had nephrectomy

- Panels A, B, and C: Rapidly fluctuating renal function, as determined by historical
measurements; or demonstrated/suspected renal artery stenosis

- Panel E only: Has required frequent emergent HD (≥3) within a year prior to first
dosing

Healthy Participants

- Renal transplant or nephrectomy